TREATMENT OF TUBERCULOSIS PATIENTS WITH EXTENSIVE DRUG RESISTANCE USING NEW ANTI-TUBERCULOSIS DRUGS IN THE CIVILIAN COMMUNITY OF ARKHANGELSK REGION

The objective: to assess treatment outcomes in tuberculosis patients with extensive drug resistance (XDR TB) treated by new anti-tuberculosis drugs in the civilian community of Arkhangelsk Region.The analysis included all cases of XDR TB registered in the civilian community of Arkhangelsk Region fro...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Tuberkulëz i bolezni lëgkikh Jg. 96; H. 7; S. 5 - 10
Hauptverfasser: GАYDА, А. I., SVESHNIKOVА, O. M., VERKHOVАYA, V. N., MАKHMАEVА, S. V., NIKISHOVА, E. I., MАRYANDYSHEV, А. O.
Format: Journal Article
Sprache:Russisch
Veröffentlicht: New Terra Publishing House 2018
Schlagworte:
new drugs
treatment
tuberculosis with extensive drug resistance
ISSN:2075-1230, 2542-1506
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The objective: to assess treatment outcomes in tuberculosis patients with extensive drug resistance (XDR TB) treated by new anti-tuberculosis drugs in the civilian community of Arkhangelsk Region.The analysis included all cases of XDR TB registered in the civilian community of Arkhangelsk Region from November 2006 to December 2013; treatment outcomes were assessed in 21 patients who were treated by regimens containing new anti-tuberculosis drugs (bedaquiline, delamanid, linezolid, clofazimine, imipenem with amoxiclav). 16 patients were treated by regimens containing 4 new anti-tuberculosis drugs. 2 patients were treated by regimen IV containing two drugs – bedaquiline, linezolid and bedaquiline, clofazimine; and 3 patients with regimens containing bedaquiline only.From November 2006 to December 2017, 175 XDR TB patients were registered in Arkhangelsk Region. The effective chemotherapy using new drugs made 57%, and mortality made 4.7%. In-take of new anti-tuberculosis drugs was accompanied side effects of minor and moderate degree.New anti-tuberculosis drugs are to be studied further in order to work out the most effective regimens for treatment of XDR TB patients.
ISSN:2075-1230
2542-1506
DOI:10.21292/2075-1230-2018-96-7-5-10